Response Genetics Inc · OTC:RGDXQ
Response Genetics — Shareholder Meeting (December 2010)
16 slides from Response Genetics's shareholder meeting presentation, Dec 1, 2010
Slide 1: Annual Shareholder Meeting
a Annual Shareholder Meeting Perec RESPONSE GENETICS erage Cee, 200 | ae! |
Slide 2: Forward-Looking Statement
Forward-Looking Statement ResponseDX tests, 1 “projects,” “may.” “could” “would,” “should,” “believes,” “expects” “anticipates,” “estimates,” “intends,” “plans” o similar expressions. These statements are based upon the curent beefs and ch “ i on, Acual results, including with ifary, may differ stat
Slide 3: Response Genetics develops and markets molecular diagnostics
Response Genetics develops and markets the vital molecular diagnostics needed to make reality in the of cancer Our goal is to deliver: The right therapy ...for each patient ...the first time™ Through Molecular Diagnostics ioihenkineaioscom
Slide 4: Response Genetics Key Facts
Response Genetics Key Facts The Company + Breakthrough, patented technology allows for the extraction and accurate analysis of genetic information from standard clinical samples, delivering results when you need them * Revenue generated from sales of ResponseDX™ tests to physicians and proprietary p
Slide 5: Drug Development
Drug Development PHARMA Greater Certainty, ‘Clinical Tale REGULATOR’ AGENCIES Safer, More Targeted ‘Clinical Tals RESPONSE GENETICS Control Over Escalating Costs
Slide 6: Pharmaceutical
Pharmaceutical Clinical Trials/Diagnostics eeneee Global clinical trial support MAGE A3 GSK Future Tests ResponseDx™ Testing ResponseDX Predictive Panels (Lung, Colon, Gastric)
Slide 7: The Response Genetic Solution: ResponseDX
The Response Genetic Solution: ResponseDX™ The Response Genetic solution provides: "Clinically relevant PCR/RT-PCR Based Tests = Associated benefit from Chemotherapy 8 ‘olon™ + ERCCI (Platinum)* + ERCCI (Platinum)* + ERCCI (Platinum)* + RRMI + EGFR (exp) (FOLFIRI)* | | - TS (FOLFOX)* + TS (Histology
Slide 8: Response Genetics Key Facts
Response Genetics Key Facts Personnel + 25% expansion in Sales Team in 2010 « Key i to Executive and Consultants » 6: David OToole (Previous CFO of Abraxis Biosciences) + Chris Meda (Former Roche Diagnostics, Bus. Dev) Recent Milestones + Launch of EML4-ALK Genetic Test for Lung Cancer + Licensing o
Slide 9: Plans for Increasing Market Share
Plans for Increasing Market Share * Expand Sales Team * Involve Pathologists in Process * Contract with Hospitals/Pathologist Groups * Clinical Trial: Addition of ResponseDX Genes into NCCN Practice Guidelines
Slide 10: Genes Developed for ResponseDx Panel are being licensed by Pharma
Genes Developed for ResponseDx™ Panel are being licensed by Pharma * Experience with Global Clinical Trials/Bridged Assays on Multiple Platforms + Competitive Pricing + Rapid Delivery of Results (5-7 days) Opportunity *More than 400 new cancer drugs from 178 companies currently in clinical trials (S
Slide 11: Growing the Response Genetics Franchise
Growing the Response Genetics Franchise I. Expand existing ResponseDX™ tests as genes that correlate with therapeutic benefit are identified 2. Build upon record revenue from ResponseDX™ tests and Pharmaceutical Clients 3. Continued sales team expansion and market coverage 4, Clinical Trials for Exp
Slide 12: Year to date Financial Results
Response Genetics, Inc. Year to date Financial Results
Slide 13: Financial Performance
Financial Performance Revenue Growth gg 3 8 8 Revenue Thousands 8 ResponseDX Accrual Adjustment. mResponseDX pharma $2,000 ~ fi | | Q408 QI109 Q209 Q309 Q409 QIIO Q2ZIO Q3l0 beiceaibeeaioreom
Slide 14: Financial Performance
Financial Performance Revenue Growth Pharma $1,274,372 $l $1,344874 $1,705,000 $2,000,000 $2,125,160 $2,592,026 Response DX $262,854 $446,234 $914,649 $1,700,000 $1,700,000 $2,000.00 $2,960,442 Response DX 2 $1,500,000
Slide 15: Performance Considerations - Sept. 30, 2010
| Performance | Considerations - Sept. 30, 2010 “Three Months ended (unaudited) ‘September 30, June 30, ‘September 30, — So me Sm =m. moe a Su» Sonue Net Income (loss) ($1,954,000) ($425,038) ($1,053,000) : Soe RESETS 2009 2009 2010 ‘Cash & Cash ‘$9,299,000 ‘$7,058,000 $5,439,000 ae Accounts: ‘$1,70
Slide 16: Slide 16
Response Genetics — Shareholder Meeting (December 2010) on 6ix